NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kinoxis Therapeutics

Kinoxis Therapeutics

Private
MelbourneHealthcare & Life Scienceshttps://kinoxistherapeutics.com/

Last Round

Grant

Dec 23, 2024

Total Funding Raised

$22.37M

Company Overview

Kinoxis Therapeutics is a biotechnology company developing novel small-molecule therapies for the treatment of neuropsychiatric disorders, including substance use disorders, agitation, and aggression.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Mental Health

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule therapeuticsdrug discoverysubstance use disordersneuropsychiatric conditionsoxytocin systemclinical-stage biotechclinical trialsdrug developmentbiopharmaaddiction medicineCNS drug developmentlicensing agreementpharmaceutical R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kinoxis Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Kinoxis Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kinoxis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 23, 2024
Series BAug 12, 2024
GrantJun 8, 2023
VC RoundDec 22, 2020
GrantSep 29, 2019
Series A
Feb 15, 2018

Key People

Founding team and executive leadership

Michael Bowen

Co-Founder And Chief Scientific Officer

Founding Team

Hugh Alsop

Chief Executive Officer

Executive Team

Kinoxis Therapeutics Investors

Notable investors and investment history

Kinoxis Therapeutics investors
InvestorRounds
National Institute on Drug AbuseGrant
CUREatorGrant
NIH RADxGrant
UniSuper ManagementSeries B
Avicella CapitalSeries B
National Institutes of Health (NIH)Grant
UniseedVC Round, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 107% MoM, reaching 505.

  • Jun 8, 2023

    Received $4M from National Institute on Drug Abuse and NIH.

Kinoxis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kinoxis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kinoxis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range18
Year Founded2017
Last FundingDec 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.